We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
Read MoreHide Full Article
Key Takeaways
Alkermes raised its offer to buy Avadel to $22.50 per share, valuing the deal at about $2.37 billion.
The move came after Avadel declared Lundbeck's unsolicited bid a Company Superior Proposal.
Avadel now says Lundbeck's offer is no longer superior following the increased offer from Alkermes.
Alkermes (ALKS - Free Report) announced that it has now increased the offer to acquire Ireland-based Avadel Pharmaceuticals (AVDL - Free Report) in a deal valued at up to $22.50 per share, representing a total transaction value of approximately $2.37 billion.
Year to date, shares of Alkermes have lost 0.3% against the industry’s growth of 16.5%.
Image Source: Zacks Investment Research
ALKS’ Battle With Lundbeck Related to Avadel Buyout
Alkermes is locked in an ongoing battle with Denmark-based H. Lundbeck A/S regarding its offer to acquire Avadel.
Last month, Alkermes announced a definitive agreement to acquire Avadel in a deal valued at up to $20.00 per share in cash, representing a total transaction value of around $2.1 billion.
Earlier this month, Lundbeck made an unsolicited offer to acquire Avadel for up to $23.00 per share, valuing the latter at approximately $2.4 billion. Following the unsolicited acquisition proposal from Lundbeck, Avadel informed Alkermes that it considered the former’s offer to be a Company Superior Proposal.
This opened a five-business-day window in which Alkermes had the option to negotiate with Avadel to revise the proposal so that Lundbeck’s bid would no longer be deemed superior.
Alkermes has eventually submitted the terms of its proposed increased offer to acquire Avadel. As a result, Avadel has now determined that Lundbeck’s proposal no longer constitutes a Company Superior Proposal.
Lundbeck was looking to buy Avadel for up to $23.00 per share, including $21.00 in cash plus a non-transferable contingent value right (“CVR”) that could pay an extra $1.00 if Lumryz and valiloxybate reach $450 million in annual net sales in the United States by 2027 and another $1.00 if they reach $700 million by 2030.
More on ALKS’ Latest Offer to Buy Avadel
Alkermes’ increased offer values Avadel at up to $22.50 per share, comprising a $21.00 cash payment and a non-transferable CVR worth up to $1.50. This CVR would be payable upon final FDA approval of Lumryz for adult idiopathic hypersomnia by December 2028, as specified in the forthcoming CVR agreement.
The increased offer from Alkermes now values Avadel for up to $2.37 billion.
AVDL’s board concluded that the CVR terms in Alkermes’ revised offer are superior to those in Lundbeck’s proposal, which the board believes is unlikely to be achieved.
As previously announced, the transaction is expected to close in the first quarter of 2026, subject to customary closing conditions.
Alkermes previously offered to purchase all outstanding ordinary shares of Avadel for $18.50 per share in cash, including CVR worth up to an additional $1.50, payable on the FDA approval of Lumryz for treating idiopathic hypersomnia in adults by the end of 2028.
Avadel’s lead commercial product Lumryz is approved as the first and only once-at-bedtime oxybate for extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy.
In the first nine months of 2025, Lumryz generated sales worth $198.1 million, reflecting an increase of almost 67% on a year-over-year basis.
Given the ongoing bidding war between Alkermes and Lundbeck, it remains to be seen whether the latter will further increase the offer to acquire Avadel or not.
ALKS' Zacks Rank & Other Key Picks
Alkermes currently sports a Zacks Rank #1 (Strong Buy).
In the past 60 days, estimates for CorMedix’s 2025 earnings per share have increased from $1.52 to $2.90. Earnings per share estimates for 2026 have moved up from $2.09 to $2.72 during the same period. CRMD stock has surged 23.8% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 27.04%.
In the past 60 days, estimates for Castle Biosciences’ 2025 loss per share have narrowed from 65 cents to 23 cents. Loss per share estimates for 2026 have narrowed from $2.10 to $1.42 during the same period. CSTL stock has rallied 30% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with an average surprise of 66.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
Key Takeaways
Alkermes (ALKS - Free Report) announced that it has now increased the offer to acquire Ireland-based Avadel Pharmaceuticals (AVDL - Free Report) in a deal valued at up to $22.50 per share, representing a total transaction value of approximately $2.37 billion.
Year to date, shares of Alkermes have lost 0.3% against the industry’s growth of 16.5%.
Image Source: Zacks Investment Research
ALKS’ Battle With Lundbeck Related to Avadel Buyout
Alkermes is locked in an ongoing battle with Denmark-based H. Lundbeck A/S regarding its offer to acquire Avadel.
Last month, Alkermes announced a definitive agreement to acquire Avadel in a deal valued at up to $20.00 per share in cash, representing a total transaction value of around $2.1 billion.
Earlier this month, Lundbeck made an unsolicited offer to acquire Avadel for up to $23.00 per share, valuing the latter at approximately $2.4 billion. Following the unsolicited acquisition proposal from Lundbeck, Avadel informed Alkermes that it considered the former’s offer to be a Company Superior Proposal.
This opened a five-business-day window in which Alkermes had the option to negotiate with Avadel to revise the proposal so that Lundbeck’s bid would no longer be deemed superior.
Alkermes has eventually submitted the terms of its proposed increased offer to acquire Avadel. As a result, Avadel has now determined that Lundbeck’s proposal no longer constitutes a Company Superior Proposal.
Lundbeck was looking to buy Avadel for up to $23.00 per share, including $21.00 in cash plus a non-transferable contingent value right (“CVR”) that could pay an extra $1.00 if Lumryz and valiloxybate reach $450 million in annual net sales in the United States by 2027 and another $1.00 if they reach $700 million by 2030.
More on ALKS’ Latest Offer to Buy Avadel
Alkermes’ increased offer values Avadel at up to $22.50 per share, comprising a $21.00 cash payment and a non-transferable CVR worth up to $1.50. This CVR would be payable upon final FDA approval of Lumryz for adult idiopathic hypersomnia by December 2028, as specified in the forthcoming CVR agreement.
The increased offer from Alkermes now values Avadel for up to $2.37 billion.
AVDL’s board concluded that the CVR terms in Alkermes’ revised offer are superior to those in Lundbeck’s proposal, which the board believes is unlikely to be achieved.
As previously announced, the transaction is expected to close in the first quarter of 2026, subject to customary closing conditions.
Alkermes previously offered to purchase all outstanding ordinary shares of Avadel for $18.50 per share in cash, including CVR worth up to an additional $1.50, payable on the FDA approval of Lumryz for treating idiopathic hypersomnia in adults by the end of 2028.
Avadel’s lead commercial product Lumryz is approved as the first and only once-at-bedtime oxybate for extended-release oral suspension for the treatment of cataplexy or excessive daytime sleepiness in patients aged seven years and older with narcolepsy.
In the first nine months of 2025, Lumryz generated sales worth $198.1 million, reflecting an increase of almost 67% on a year-over-year basis.
Given the ongoing bidding war between Alkermes and Lundbeck, it remains to be seen whether the latter will further increase the offer to acquire Avadel or not.
ALKS' Zacks Rank & Other Key Picks
Alkermes currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) and Castle Biosciences (CSTL - Free Report) , each sporting a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for CorMedix’s 2025 earnings per share have increased from $1.52 to $2.90. Earnings per share estimates for 2026 have moved up from $2.09 to $2.72 during the same period. CRMD stock has surged 23.8% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 27.04%.
In the past 60 days, estimates for Castle Biosciences’ 2025 loss per share have narrowed from 65 cents to 23 cents. Loss per share estimates for 2026 have narrowed from $2.10 to $1.42 during the same period. CSTL stock has rallied 30% year to date.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with an average surprise of 66.11%.